Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 16;30(24):5521-5526.
doi: 10.1158/1078-0432.CCR-24-1729.

FDA Approval Summary: Polatuzumab Vedotin in the First-Line Treatment of Select Large B-Cell Lymphomas

Maryam Sarraf Yazdy  1 , Yvette L Kasamon  1 , Wenjuan Gu  1 , Lisa R Rodriguez  1 , Susan Jin  1 , Vishal Bhatnagar  1 , Nicholas C Richardson  1 , Marc R Theoret  1   2 , Richard Pazdur  1   2 , Nicole J Gormley  1
Affiliations

FDA Approval Summary: Polatuzumab Vedotin in the First-Line Treatment of Select Large B-Cell Lymphomas

Maryam Sarraf Yazdy et al. Clin Cancer Res. .

Abstract

In April 2023, the U.S. FDA granted regular approval to polatuzumab vedotin-piiq in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (pola+R-CHP) for adult patients who have previously untreated diffuse large B-cell lymphoma, not otherwise specified, or high-grade B-cell lymphoma and who have an International Prognostic Index score of 2 or greater. Approval was based on POLARIX, a randomized, double-blinded, placebo-controlled trial evaluating the superiority of substituting vincristine with polatuzumab vedotin in the rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone regimen as first-line therapy for patients with large B-cell lymphoma. Efficacy was based on investigator-assessed progression-free survival (PFS) in 879 patients who were randomized to receive pola+R-CHP or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, followed by two cycles of rituximab alone. PFS was statistically significantly longer with pola+R-CHP, with an HR of 0.73 (95% confidence interval, 0.57-0.95) and log-rank P value of 0.0177 (two-sided α = 0.05). There was no improvement demonstrated in the key secondary endpoints of the complete response rate at the end of therapy or overall survival (OS). Several issues raised uncertainty about the benefit-risk profile of polatuzumab vedotin in this curative-intent setting, including the modest PFS benefit of pola+R-CHP and lack of OS benefit. The application was therefore presented at an Oncology Drugs Advisory Committee. This article summarizes key aspects of the regulatory review, including perspectives on PFS and OS results and other endpoints.

PubMed Disclaimer

Conflict of interest statement

Disclosure of Potential Conflicts of Interest: The authors report no financial interests or relationships with the commercial sponsors of any products discussed in this report.

Figures

Figure 1:
Figure 1:
Kaplan-Meier plots of investigator-assessed progression-free and overall survival in POLARIX. A) Primary analysis of PFS per investigator in the ITT population. B) Final overall survival analysis in the ITT population. C) PFS in the DLBCL, NOS subgroup at the time of primary analysis. D) Final overall survival analysis in the DLBCL, NOS subgroup. Source: FDA analysis.
Figure 2:
Figure 2:
Forest Plots of progression-free survival (A) and overall survival (B) by type of non-Hodgkin lymphoma. Source: FDA analysis.
See this image and copyright information in PMC

References

    1. Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2020;38(2):155–65 doi 10.1200/JCO.19.00172. - DOI - PMC - PubMed
    1. U.S. Food and Drug Administration. Polivy (polatuzumab vedotin-piiq) BLA 761121 clinical pharmacology review, June 2019. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761121Orig1s000T.... Accessed February 1, 2023.
    1. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 1993;328(14):1002–6 doi 10.1056/NEJM199304083281404. - DOI - PubMed
    1. U.S. Food and Drug Administration. BLA 103705/s5209 (Rituxan) clinical and statistical reviews, February 2006.
    1. Genentech, Inc. RITUXAN (rituximab) injection, for intravenous use: U.S. Prescribing Information, December 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl... Accessed February 12, 2023.

MeSH terms

LinkOut - more resources